GridAI Technologies Corp.

GridAI Technologies Corp. is a diversified technology and life sciences company operating in two main areas: energy orchestration and grid optimization software, and legacy biopharmaceutical development. The company changed its name from Entero Therapeutics, Inc. to GridAI Technologies Corp. on December 1, 2025, and its Nasdaq symbol from ENTO to GRDX. On September 30, 2025, the company acquired 100% of Grid AI Corp., a Nevada corporation. At the time of acquisition, Grid AI Corp. owned 75% of AMPX UK Holdings, a Cayman Islands company, which holds the operating subsidiary AMPX Limited. Grid AI Corp. and its subsidiaries, including AMPX, became consolidated subsidiaries of GridAI Technologies Corp. Grid AI Corp. develops software and services to accelerate power availability and optimize energy infrastructure for artificial intelligence (AI) data centers and other large energy users. Grid AI Corp. is developing an AI data center platform to use and optimize distributed energy resources, including battery energy storage systems, on-site generation, and grid interconnections, which currently generates no revenue. Grid AI Corp.'s commercial pipeline is being re-established through consulting-led engagements and business development. For the year ended December 31, 2025, the company's consolidated financial statements include Grid AI Corp. and AMPX results from September 30, 2025. The biopharmaceutical segment focuses on Adrulipase for exocrine pancreatic insufficiency. Prior to the Grid AI Corp. acquisition, the company primarily operated as a clinical-stage biopharmaceutical company focused on targeted, non-systemic therapies for gastrointestinal diseases. Non-systemic therapies are non-absorbable drugs that act locally without reaching systemic circulation. In May 2024, the company changed its name from First Wave BioPharma, Inc. to Entero Therapeutics, Inc.